Drugs / SAN007
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02871479 | Apr 2017 → Aug 2018 | atopic eczema | Santalis Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAN007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02871479 ↗ |
| Route | Topical | “5% EISO in a cream formulation applied twice a day for up to 28 days.” NCT02871479 ↗ |